Supplemental Figure S1: Knockdown of BRCA1 or BRCA2 sensitizes Hela cells to PBD payload and PBD-based ADC in vitro. Supplemental Figure S2: Genetic deletion of BRCA1 sensitizes cells to PBD-based ADC. Supplemental Table S1: BRCA mutation(s) in patient-derived xenograft models. Supplemental Figure S3: Mean tumor volume graphs of 23 BRCA-deficient PDX tumors response to PBD-ADC treatment compared to untreated group. Supplemental Figure S4: Mean tumor volume graphs of BRCA wild-type PDX tumors response to PBD-ADC treatment compared to untreated group. Supplemental Figure S5: Representative IHC images of 5T4 staining in PDX models. Supplemental Figure S6: No in vivo efficacy was observed in tumor model DMS-114 that does not express 5T4.